Pharmamarketeer
FDA Approves Cord Blood Stem Cell Product, Omisirge, for Blood Cancer Patients

FDA Approves Cord Blood Stem Cell Product, Omisirge, for Blood Cancer Patients

FDA Approves Cord Blood Stem Cell Product, Omisirge, for Blood Cancer Patients

The U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic cord blood-based cell therapy, to cut the risk of infection in patients with blood cancer following a myeloablative treatment, such as radiation or chemotherapy.

Medhc-fases-banner
Advertentie(s)